Anebulo Pharmaceuticals (ANEB) Competitors $2.44 +0.04 (+1.67%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$2.44 0.00 (0.00%) As of 08/14/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. CMPS, SNDL, FLGC, RGNX, ERAS, MBX, PVLA, CMPX, TECX, and ATXSShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include COMPASS Pathways (CMPS), SNDL (SNDL), Flora Growth (FLGC), REGENXBIO (RGNX), Erasca (ERAS), MBX Biosciences (MBX), Palvella Therapeutics (PVLA), Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Its Competitors COMPASS Pathways SNDL Flora Growth REGENXBIO Erasca MBX Biosciences Palvella Therapeutics Compass Therapeutics Tectonic Therapeutic Astria Therapeutics Anebulo Pharmaceuticals (NASDAQ:ANEB) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Do institutionals & insiders believe in ANEB or CMPS? 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is ANEB or CMPS more profitable? COMPASS Pathways' return on equity of -87.89% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -90.11% -84.53% COMPASS Pathways N/A -87.89%-57.77% Which has more risk & volatility, ANEB or CMPS? Anebulo Pharmaceuticals has a beta of -0.88, indicating that its share price is 188% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500. Which has higher valuation and earnings, ANEB or CMPS? Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-9.38COMPASS PathwaysN/AN/A-$155.12M-$1.84-2.30 Does the media favor ANEB or CMPS? In the previous week, COMPASS Pathways had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 5 mentions for COMPASS Pathways and 4 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.79 beat COMPASS Pathways' score of 0.30 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anebulo Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COMPASS Pathways 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ANEB or CMPS? Anebulo Pharmaceuticals currently has a consensus target price of $5.50, indicating a potential upside of 125.41%. COMPASS Pathways has a consensus target price of $16.29, indicating a potential upside of 284.10%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Anebulo Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50COMPASS Pathways 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 SummaryCOMPASS Pathways beats Anebulo Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.60M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-9.3820.4930.2825.74Price / SalesN/A356.37460.47115.79Price / CashN/A43.0338.2159.48Price / Book16.278.608.856.15Net Income-$8.20M-$54.65M$3.25B$265.06M7 Day Performance1.24%5.86%3.72%2.60%1 Month Performance55.41%8.86%5.86%2.83%1 Year Performance25.77%13.33%30.34%25.58% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.2473 of 5 stars$2.44+1.7%$5.50+125.4%+26.8%$98.60MN/A-9.384Short Interest ↑CMPSCOMPASS Pathways2.5957 of 5 stars$4.58-0.5%$16.29+256.0%-38.3%$438.93MN/A-2.49120SNDLSNDL2.2303 of 5 stars$1.66+0.9%$4.00+141.7%-2.3%$434.90M$671.81M-6.132,516Options VolumeGap DownFLGCFlora Growth3.1868 of 5 stars$19.00-11.5%$156.00+721.1%-33.8%$428.83M$59.51M-21.59280Positive NewsShort Interest ↓High Trading VolumeRGNXREGENXBIO4.241 of 5 stars$8.43+1.2%$29.00+244.1%-24.1%$424.50M$83.33M-2.72370Gap DownERASErasca2.4372 of 5 stars$1.49+6.1%$4.57+207.8%-39.4%$420.68MN/A-2.40120News CoverageEarnings ReportMBXMBX Biosciences2.5583 of 5 stars$12.44-0.8%$37.63+202.6%N/A$418.70MN/A0.0036News CoverageGap UpPVLAPalvella Therapeutics1.7439 of 5 stars$37.50+0.8%$52.22+39.3%N/A$414.75M$42.81M-3.10N/ANews CoverageCMPXCompass Therapeutics2.7458 of 5 stars$3.00+5.1%$12.67+322.9%+158.8%$414.16M$850K-7.3020Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownTECXTectonic Therapeutic2.4454 of 5 stars$22.24+5.1%$80.33+261.2%+52.4%$413.26MN/A-3.03120ATXSAstria Therapeutics2.6866 of 5 stars$7.12+3.3%$29.00+307.3%-32.3%$401.78MN/A-3.8130News CoverageEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies COMPASS Pathways Alternatives SNDL Alternatives Flora Growth Alternatives REGENXBIO Alternatives Erasca Alternatives MBX Biosciences Alternatives Palvella Therapeutics Alternatives Compass Therapeutics Alternatives Tectonic Therapeutic Alternatives Astria Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access